Potential for phosphodiesterase inhibitors in the management of autoimmune diseases

Abstract

Phosphodiesterases (PDEs) and their substrates, cAMP and cGMP, are ubiquitously expressed in the immune system. Inhibiting PDEs may represent a novel approach for regulating immune functions and have a therapeutic potential in the management of autoimmune diseases. Phosphodiesterase inhibitors (PDEi) have proved effective in clinical trials in the management of pulmonary artery hypertension and Raynaud's phenomenon. Data from animal models suggest that the immunomodulatory effect of PDEi may have a therapeutic potential in the management of diseases such as multiple sclerosis and rheumatoid arthritis. The antifibrotic potential of PDEi, as suggested by animal experiments, if proven in further studies will be a major step in the treatment of fibrosing diseases such as scleroderma and idiopathic pulmonary fibrosis. Drug Dev Res 72:772-778,

Tadalafil: 15 years' journey in male erectile dysfunction and beyond

“…Studies showed that tadalafil significantly decreased symptoms including frequency, and duration of attacks (Roustit et al, 2013). In animal models, tadalafil proved efficacy in alleviating symptoms of osteoarthritis, a mechanism that involved reduction of cell influx and Tumor necrosis factor (TNF) release (Shenoy, Agarwal, Agarwal, Misra, & Naik, 2011).…”

Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential

“…50 Manifestations of systemic sclerosis include Raynaud's phenomenon, lung fibrosis, and pulmonary artery hypertension (PAH). 51 An immune response is generated by antigens in these patients. T-cells are activated early in the disease process, and these, along with other inflammatory cells such as macrophages, monocytes, mast cells, and eosinophils, infiltrate tissues.…”